Diagonal Bio AB first quarter (Q1 2024)
“The end of last year was marked by our focus on creating the business platform to generate the company's initial revenue in 2024. We continue and gear up on the set path with a focus on generating revenue”.Summary of Q1 report 2024 2024-01-01 — 2024-03-31 (January — March 2024) • Net sales amounted to 0 KSEK (0 KSEK), capitalised development contributed with 250 KSEK (1 030 KSEK), and other operating income amounted to 5 KSEK (6 KSEK). • Operating profit amounted to -2 727 KSEK (-3 701 KSEK). • Operating profit per net weighted average share amounted to -0.07 SEK (-0.11 SEK).